In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma.
The World Web Times - worldwebtimes.comThe World Web Times - worldwebtimes.com - The News And Times | Israel And The Middle East
